Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis
IntroductionThere has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD). However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate. Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) as a plasma...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.1028448/full |
| _version_ | 1797951465745022976 |
|---|---|
| author | Jung-Min Pyun Young Chul Youn Young Ho Park SangYun Kim |
| author_facet | Jung-Min Pyun Young Chul Youn Young Ho Park SangYun Kim |
| author_sort | Jung-Min Pyun |
| collection | DOAJ |
| description | IntroductionThere has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD). However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate. Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) as a plasma biomarker detecting oligomerization tendency is available in the clinical practice.Main textWe suggest how to interpret the results of plasma biomarker for amyloidopathy using MDS-OAβ with neuropsychological test, brain magnetic resonance imaging (MRI), and amyloid PET for AD diagnosis. Combination of each test result differentiates various stages of AD, other neurodegenerative diseases, or cognitive impairment due to the causes other than neurodegeneration.DiscussionA systematic interpretation strategy could support accurate diagnosis and staging of AD. Moreover, comprehensive use of biomarkers that target amyloidopathy such as amyloid PET on brain amyloid plaque and MDS-OAβ on amyloid-β oligomerization tendency can complement to gain advanced insights on amyloid-β dynamics in AD. |
| first_indexed | 2024-04-10T22:30:59Z |
| format | Article |
| id | doaj.art-baaf5866e19947cabce550c6cee76d4b |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-10T22:30:59Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-baaf5866e19947cabce550c6cee76d4b2023-01-17T04:56:08ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-01-011310.3389/fneur.2022.10284481028448Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosisJung-Min Pyun0Young Chul Youn1Young Ho Park2SangYun Kim3Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of KoreaDepartment of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of KoreaDepartment of Neurology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of KoreaIntroductionThere has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD). However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate. Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) as a plasma biomarker detecting oligomerization tendency is available in the clinical practice.Main textWe suggest how to interpret the results of plasma biomarker for amyloidopathy using MDS-OAβ with neuropsychological test, brain magnetic resonance imaging (MRI), and amyloid PET for AD diagnosis. Combination of each test result differentiates various stages of AD, other neurodegenerative diseases, or cognitive impairment due to the causes other than neurodegeneration.DiscussionA systematic interpretation strategy could support accurate diagnosis and staging of AD. Moreover, comprehensive use of biomarkers that target amyloidopathy such as amyloid PET on brain amyloid plaque and MDS-OAβ on amyloid-β oligomerization tendency can complement to gain advanced insights on amyloid-β dynamics in AD.https://www.frontiersin.org/articles/10.3389/fneur.2022.1028448/fullAlzheimer's diseaseblood-based biomarkeramyloid-βoligomerization tendencydiagnosisneuropsychological test |
| spellingShingle | Jung-Min Pyun Young Chul Youn Young Ho Park SangYun Kim Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis Frontiers in Neurology Alzheimer's disease blood-based biomarker amyloid-β oligomerization tendency diagnosis neuropsychological test |
| title | Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis |
| title_full | Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis |
| title_fullStr | Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis |
| title_full_unstemmed | Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis |
| title_short | Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis |
| title_sort | integration of amyloid β oligomerization tendency as a plasma biomarker in alzheimer s disease diagnosis |
| topic | Alzheimer's disease blood-based biomarker amyloid-β oligomerization tendency diagnosis neuropsychological test |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.1028448/full |
| work_keys_str_mv | AT jungminpyun integrationofamyloidboligomerizationtendencyasaplasmabiomarkerinalzheimersdiseasediagnosis AT youngchulyoun integrationofamyloidboligomerizationtendencyasaplasmabiomarkerinalzheimersdiseasediagnosis AT younghopark integrationofamyloidboligomerizationtendencyasaplasmabiomarkerinalzheimersdiseasediagnosis AT sangyunkim integrationofamyloidboligomerizationtendencyasaplasmabiomarkerinalzheimersdiseasediagnosis |